Related Experiment Video

Updated: Jun 3, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.8K

Cardiorenal Disease and Heart Failure with Preserved Ejection Fraction: Two Sides of the Same Coin

Gonzalo Núñez-Marín1,2, Enrique Santas1,2,3

  • 1Cardiology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.

Cardiorenal Medicine
|January 8, 2025
PubMed

Insights

Heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD) share a strong link, worsening patient outcomes. New therapies like SGLT2 inhibitors offer cardio- and renoprotective benefits for this population.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD) exhibit a significant pathophysiological interrelationship.
  • The combination of HFpEF and CKD is associated with a poorer prognosis.

Purpose of the Study:

  • To review the epidemiological burden and pathophysiological interplay between HFpEF and CKD.
  • To discuss diagnostic and screening controversies for HFpEF in CKD patients.
  • To highlight effective therapeutic strategies for this high-risk population.

Main Methods:

  • Literature review of epidemiological data.
  • Analysis of pathophysiological mechanisms.
  • Evaluation of current and emerging therapeutic options.

Main Results:

  • HFpEF screening is recommended in CKD patients, with careful consideration of diagnostic tool utility.
  • Recent advancements in optimal medical therapy have shown significant promise.
  • SGLT2 inhibitors, finerenone, and semaglutide demonstrate consistent cardio- and renoprotective effects.

Conclusions:

  • Screening for HFpEF in CKD patients is crucial due to prevalence and prognostic impact.
  • Novel pharmacotherapies offer improved symptom management and prognosis.
  • SGLT2 inhibitors, finerenone, and semaglutide are key agents for managing combined HFpEF and CKD.
Abstract

Keywords:
Cardiorenal diseaseChronic kidney diseaseCongestionHeart failureHeart failure with preserved ejection fraction

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

20.3K

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
62
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314